Nicotinamide Metabolites Accumulate in the Tissues of Uremic Rats

Journal of Renal Nutrition

Volumn 18, Issue 1, 2008, Pages 56-59

  Rutkowski, Przemysław ^a   Slominska, Ewa M ^a   Wołyniec, Wojciech ^a   Smoleński, Ryszard T ^a   Szolkiewicz, Marek ^a   Świerczyński, Julian ^a   Rutkowski, Bolesław ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; N METHYL 2PYRIDONE 5 CARBOXAMIDE; N(1) METHYL 4 PYRIDONE 5 CARBOXAMIDE; N(1)-METHYL-4-PYRIDONE-5-CARBOXAMIDE; N-METHYL-2PYRIDONE-5-CARBOXAMIDE; NICOTINAMIDE; PYRIDONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BLOOD; DISEASE MODEL; MALE; METABOLISM; NEPHRECTOMY; RAT; REFERENCE VALUE; ULTRAFILTRATION; UREMIA; WISTAR RAT;

ANIMALS; DISEASE MODELS, ANIMAL; MALE; NEPHRECTOMY; NIACINAMIDE; PYRIDONES; RATS; RATS, WISTAR; REFERENCE VALUES; ULTRAFILTRATION; UREMIA;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 37049018383     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2007.10.012     Document Type: Article

References (17)

1. Vanholder R., De Smet R., Glorieux G., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 63 (2003) 1934-1943
2. Massry S.G. Is parathyroid hormone a uremic toxin?. Nephron 19 (1977) 125-130
3. Bergstrom J., and Furst P. Uremic toxins. Kidney Int 13 Suppl 8 (1978) S9-S12
4. Slominska E.M., Smolenski R., Szolkiewicz M., et al. Accumulation of plasma N-methyl-2-pyridone-5-carboxamide in patients with chronic renal failure. Mol Cell Biochem 231 (2002) 83-88
5. Rutkowski B., Slominska E., Szolkiewicz M., et al. N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin?. Kidney Int 84 Suppl (2003) S19-S21
6. Rutkowski P., and Rutkowski B. Novel family of uremic toxins. Nephrol Dial Pol 10 (2006) 152-155
7. Rutkowski B., Swierczynski J., Slominska E., et al. Disturbances of purine nucleotide metabolism in uremia. Semin Nephrol 24 (2004) 479-483
8. Slominska E.M., Kowalik K., Smolenski R.T., et al. Accumulation of poly(ADP-ribose) polymerase inhibitors in children with chronic renal failure. Pediatr Nephrol 21 (2006) 800-806
9. Slominska E.M., Adamski P., Lipinski M., et al. Liquid chromatographic/mass spectrometric procedure for measurement of NAD catabolites in human and rat plasma and urine. Nucleosides Nucleotides Nucleic Acids 25 (2006) 1245-1249
10. Marescau B., D'Hooge R., Possemiers I., et al. Guanidino compound levels in brain regions of non-dialyzed uremic patients. Neurochem Int 27 (1995) 227-237
11. De Deyn P.P., D'Hooge R., Van Bogaert P.P., et al. Endogenous guanidino compounds as uremic neurotoxins. Kidney Int 59 (2001) 77-83
12. Kikuchi T., Orita Y., Ando A., et al. Liquid-chromatographic determination of guanidino compounds in plasma and erythrocyte of normal persons and uremic patients. Clin Chem 27 (1981) 1899-1902
13. Tanaka A., Takahashi Y., Mizokuchi M., et al. Plasma, urinary, and erythrocyte concentrations of guanidino compounds in patients with chronic renal failure. Ren Fail 21 (1999) 499-514
14. Kinlen L.J., Eastwood J.B., Kerr D.N., et al. Cancer in patients receiving dialysis. Br Med J [Clin Res] 280 (1980) 1401-1403
15. Maisonneuve P., Agodoa L., Gellert R., et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354 (1999) 93-99
16. Newstead C.G. Cancer risk in patients on dialysis. Lancet 354 (1999) 90-91
17. Amann K., Tyralla K., Gross M.L., et al. Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 60 Suppl 1 (2003) S13-S21